Does EVOLOCUMAB Cause Therapy non-responder? 540 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 540 reports of Therapy non-responder have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.4% of all adverse event reports for EVOLOCUMAB.
540
Reports of Therapy non-responder with EVOLOCUMAB
0.4%
of all EVOLOCUMAB reports
3
Deaths
4
Hospitalizations
How Dangerous Is Therapy non-responder From EVOLOCUMAB?
Of the 540 reports, 3 (0.6%) resulted in death, 4 (0.7%) required hospitalization, and 1 (0.2%) were considered life-threatening.
Is Therapy non-responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 540 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Therapy non-responder?
ETANERCEPT (3,472)
APREMILAST (3,360)
METHOTREXATE (2,965)
RITUXIMAB (2,731)
ADALIMUMAB (2,595)
PREDNISONE (2,563)
TREPROSTINIL (2,289)
INFLIXIMAB (2,122)
TOCILIZUMAB (1,775)
HYDROXYCHLOROQUINE (1,699)
Which EVOLOCUMAB Alternatives Have Lower Therapy non-responder Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE